On June 11th, Gelon Hui announced that its wholly-owned subsidiary, Ganlei Pharmaceutical Co., Ltd., dedicated to researching, developing, and commercializing new drugs for metabolic dysfunction-associated steatohepatitis (MASH), made a poster presentation at the European Association for the Study of the Liver (EASL) 2024 conference, which was held in Milan, Italy from June 5th to June 8th, 2024.

A poster entitled "ASC41, a selective THRβ agonist, significantly reduces liver fat and alanine aminotransferase (ALT) in MASH patients confirmed by biopsy after 12 weeks of treatment: a mid-term analysis of a 52-week liver biopsy continuous study" showed a clinically significant reduction in liver fat, ALT and aspartate aminotransferase (AST) in biopsy-proven MASH patients after 12 weeks of ASC41 treatment, with the data for ALT and AST distinguishing ASC41 significantly from other thyroid hormone receptor β (THRβ) agonists currently in clinical or commercial stages. In addition, the baseline characteristics of ASC41 (conducted in China) and resmetirom's phase II clinical trial are similar, but ASC41 has a lower body mass index (BMI) and more male participants.